SecBot SecBot

GPCR

Structure Therapeutics Inc.
Nasdaq· Pharmaceutical Preparations· Inc. E9· CIK 0001888886 Biotech & Drug Discovery
$18.57 −1.43 (−7.15%)
Nov 16 4:00 PM ET · prev $20.00
Market cap
$1.4B
Small cap
Consensus
Buy
91% Buy or better · 23 analysts
Median target
$100.50
+441% · range $70.00–145.00
1 year
−50.4%
from $37.44 · Nov 17
30 days
−15.6%
from $22.01
52-week range
$18.57–93.79
at the low
Avg volume 20D
966.7K
shares / day
Short interest
5.93M
≈8.3% of shares · −17.1%
Days to cover
6.5
at average volume
Insider net
−$3.5M
0 buyers · 3 sellers · since Mar 19
New fund stakes
0
Q3 2026 13F · 1 exit
Filing reports
8
analyzed by SecBot
SecBot read MIXED 4 reports · 90 days
Balance 0 bearish · 0 bullish · 4 neutral oldest → newest, height = score
Avg score ·High conf. 2/4

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBEARISH

    3 insiders sold $3.5M.

  • InstitutionsMIXED

    Q3 2026: 17 added (0 new), 23 trimmed or exited.

  • AnalystsBULLISH

    21 of 23 rate it Buy or better. Every target is above the price.

  • EstimatesFALLING

    Current-quarter EPS estimate −$0.187 → −$0.241 over 90 days. 0 up, 1 down in 30 days.

  • Short sellersCOVERING

    Short interest −17.1% to 5.93M shares. 6.5 days to cover, ≈8.3% of shares.

  • TrendDOWNTREND

    32% below its 50-day average. New closing low $18.57 on Nov 16.

  • SocialQUIET

    No Reddit mentions this week. Last mention Nov 8.

Who's buying

13F· Q3 2026
0
new positions
1
exit
FundMoveSharesValue
PRINCIPAL FINANCIAL GROUP INCTRIM1,264,946$39.6M
Aberdeen Group plcADD858,784$26.9M
BlackRock, Inc.ADD705,946$22.1M
JPMORGAN CHASE & CODOUBLED546,189$17.9M
AMERICAN CENTURY COMPANIES INCNEAR_EXIT303,882$9.5M
FRANKLIN TEMPLETON INCTRIM371,271$7.6M
HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUNDTRIM135,299$4.2M
MARSHALL WACE, LLPTRIM108,366$3.4M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

23 analysts
Buy 91% rate it Buy or better
Strong Buy8Buy13Hold2Sell0Strong Sell0
12-month targets · 14 analysts

Price is below the lowest target. Median implies +441%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Sep 9, 2026Citizens
REITERATE
REITERATEMarket Outperform
Aug 7, 2026Citigroup
MAINTAIN
MAINTAINBuy
Aug 7, 2026Citizens
MAINTAIN
MAINTAINMarket Outperform
Jun 11, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINBuy

Insider ledger

Form 4
$0
bought · 0 insiders
$3.5M
sold · 3 insiders
DateInsiderTypeValue
Sep 21, 2026
Coll Crespo Blas
CHIEF MEDICAL OFFICER
Sep 21, 2026
CONVERT12,024 sh
Sep 21, 2026
Coll Crespo Blas
CHIEF MEDICAL OFFICER
Sep 21, 2026
CONVERT4,008 sh
Sep 21, 2026
Coll Crespo Blas
CHIEF MEDICAL OFFICER
Sep 21, 2026
SELL$144.9K
Sep 18, 2026
Coll Crespo Blas
CHIEF MEDICAL OFFICER
Sep 18, 2026
TAX W/H$124.0K
Sep 1, 2026
Lin Xichen
CHIEF SCIENTIFIC OFFICER
Sep 1, 2026
SELL$4.8K
Sep 1, 2026
Lin Xichen
CHIEF SCIENTIFIC OFFICER
Sep 1, 2026
SELL$59.6K
Sep 1, 2026
Lin Xichen
CHIEF SCIENTIFIC OFFICER
Sep 1, 2026
SELL$214.3K
Sep 1, 2026
Lin Xichen
CHIEF SCIENTIFIC OFFICER
Sep 1, 2026
CONVERT17,817 sh

Earnings setup

Estimates
−$0.24
EPS estimate, this quarter
−29%
estimate change, 90 days
0↑ 1↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.24-$0.57–$2.02-3.4%$0.00
Next Q🔒 Fresh data, subscribers only
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Short side

FINRA· Oct 30, 2026
5,927,622
shares short
-17.1%
vs prior settlement
6.5
days to cover
≈8.3%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 16, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Nov 16, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Nov 9, 2026 SEC
Structure Therapeutics reported Q3 2026 net loss of $144.8M, wider than the $65.7M loss in Q3 2025, driven by…
PRESS-RELEASE · Impact 4/10
Nov 9, 2026 Earnings
Structure Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights
Structure Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights
Sep 30, 2026 Inst.
PRINCIPAL FINANCIAL GROUP INC · TRIM
1,264,946 shares ($39.6M)
Sep 30, 2026 Inst.
Aberdeen Group plc · ADD
858,784 shares ($26.9M)
Sep 21, 2026 Insider
Coll Crespo Blas disposed of 12,024 shares
CHIEF MEDICAL OFFICER
Sep 21, 2026 Insider
Coll Crespo Blas acquired 4,008 shares
CHIEF MEDICAL OFFICER
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
3 drugs tracked · Drug pipeline →
Recent
Nov 9, 2026
Earnings
Structure Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights
Structure Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights
Nov 4, 2026
Press release
Structure Therapeutics to Participate in the Jefferies Global Healthcare Conference
Structure Therapeutics to Participate in the Jefferies Global Healthcare Conference In London, UK
Nov 4, 2026
Earnings date
GPCR Q3 2026 Earnings After Market Close · 2026-11-04
Oct 19, 2026
Company news
Structure Therapeutics Announces Multiple Upcoming Presentations at ObesityWeek® 2026
Structure Therapeutics' poster presentations at The Obesity Society's Annual Meeting...
Sep 3, 2026
Press release
Structure Therapeutics to Participate in Upcoming Healthcare Investor Conferences
Structure Therapeutics Participates in Upcoming Investor Conferences

SecBot reports

8 filings · 2 press releases · 0 bullish · 1 bearish · 2 mixed · 5 neutral
All GPCR filing & press-release reports (10)